TITLE

Escitalopram for Menopausal Hot Flashes

PUB. DATE
March 2011
SOURCE
Travel Medicine Advisor;Mar2011 Supplement, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses various topics related to pharmacology. A study for escitalopram treatment of hot flashes in 205 menopausal women reveals the efficiency of the drug to reduce hot flashes severity. Meanwhile, a retrospective cohort study by Kaiser Permanente researchers in Southern California reveals that herpes zoster vaccine reduces shingles in adult by 55%. Moreover, the U.S. Food and Drug Administration (FDA) approves drugs such as vilazodone hydrochloride and transmucosal fentanyl.
ACCESSION #
58663209

 

Related Articles

  • FDA actions.  // Neurology Alert;Aug2013 Pharmacology Watch, p2 

    The article reports on the approval of the supplement paroxetine, a selective serotonin reuptake inhibitor (SSRI) by the U.S. Food and Drug Administration (FDA) for the treatment of hot flashes during menopause. Paroxetine is said to have the same active ingredient in the antidepressant Paxil....

  • product showcase.  // Pharmacy Today;Aug2013, Vol. 19 Issue 8, p17 

    The article offers pharmaceutical related news briefs in the U.S. The Food and Drug Administration (FDA) approves the Xpert MTB/RIF Assay (Cepheid) for the detection of tuberculosis (TB) bacteria. FDA approves Brisdelle drug for the treatment of hot flashes associated with menopause. Dr. Reddy's...

  • FDA Should Not Approve Two Drugs For Hot Flashes. Holzer, Barbara // Public Citizen News;May/Jun2013, Vol. 33 Issue 3, p12 

    The author suggests that the drugs that were used previously approved for other purposes should not be approved by the U.S. Food and Drug Administration (FDA) for hot flashes that are experienced by women in menopause. She states that these two drugs named paroxetine and gabapentin displayed...

  • Vaccine debate.  // Journal of Holistic Healthcare;Sep2008, Vol. 5 Issue 3, p4 

    The article reports on the debate concerning Zostavax, a vaccine for adult shingles, in the U.S. It states that the drug has been approved by the Food and Drug Administration (FDA) for use in adults age 60 and older. According to Dr. David Markovitz of FDA, the said drug has not been tested on...

  • Herpes Zoster Virus Vaccine (Zostavax) for the Prevention of Shingles. DeYoung, G. Robert; Baty, Philip J. // American Family Physician;6/15/2007, Vol. 75 Issue 12, p1843 

    The article focuses on the approval of the herpes zoster vaccine for the prevention of shingles in persons 60 years or older by the U.S. Food and Drug Administration (FDA). It mentions that the Advisory Committee on Immunization Practices (ACIP) has recommended the use of the vaccine for the...

  • Approvals, Submission, and Important Labeling Changes for US Marketed Pharmaceuticals. Baker, Danial E. // Hospital Pharmacy;Jun2012, Vol. 47 Issue 6, p471 

    Several tables are presented which provide data related to drug approvals, subsmission, and labeling which include the new drugs being approved by the U.S. Food and Drug Administration (FDA) from March 17 to April 13, 2012, newly FDA-approved dosage forms and indications from March 17 to April...

  • News from the FDA. Pennachio, Dorothy L. // Patient Care;Dec2003, Vol. 37 Issue 12, p5 

    Provides information on newly-approved drugs by the U.S. Food and Drug Administration in December 2003. Estradiol topical emulsion; Eplerenone; Memantine HCl; Zolmitriptan.

  • Pipeline preview.  // Formulary;Nov2003, Vol. 38 Issue 11, p617 

    Provides information on the status of medications or drugs pending approval by the U.S. Food and Drug Administration as of November 2003. Recommendations for approval; Approvable designations; Orphan drug designations; Fast-track designations; Recommendations against approval; Non-approvable...

  • FDA actions.  // Internal Medicine Alert;4/15/2011 Pharmacology Watch, p2 

    The article reports on the new drugs approved by the U.S. Food and Drug Administration including the vaccine Zostavax for the prevention of shingles, Ipilimumab for the treatment of late stage melanoma, and Belimumab for the treatment of systemic lupus erythematosus.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics